Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that it filed its annual report on Form 20-F (the “Form 20-F”) for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 26, 2022. The Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Company’s website at www.ambrx.com.
The Company will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and holders of its American Depositary Shares upon request. Requests should be directed in writing by email to ir@ambrx.com.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005647/en/
Contacts
Ambrx Biopharma Inc.
INVESTORS
Laurence Watts, Managing Director
Gilmartin Group, LLC.
619-916-7620
ir@ambrx.com
MEDIA
media@ambrx.com
